WuXi Biologics (Cayman) Inc. Share Price Hong Kong S.E.
Equities
2269
KYG970081090
Biotechnology & Medical Research
Sales 2024 * | 18.18B 2.51B 19.61B 210B | Sales 2025 * | 21.76B 3B 23.47B 251B | Capitalization | 53.84B 7.44B 58.07B 620B |
---|---|---|---|---|---|
Net income 2024 * | 3.89B 538M 4.2B 44.85B | Net income 2025 * | 4.93B 680M 5.31B 56.77B | EV / Sales 2024 * | 2.57 x |
Net cash position 2024 * | 7.11B 982M 7.67B 81.95B | Net cash position 2025 * | 8.06B 1.11B 8.7B 92.93B | EV / Sales 2025 * | 2.1 x |
P/E ratio 2024 * |
14.3
x | P/E ratio 2025 * |
11.2
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.47% |
Latest transcript on WuXi Biologics (Cayman) Inc.
Managers | Title | Age | Since |
---|---|---|---|
Zhi Sheng Chen
CEO | Chief Executive Officer | 52 | 01/11/01 |
Ming Tu
DFI | Director of Finance/CFO | 54 | 23/21/23 |
Gu Jijie
CTO | Chief Tech/Sci/R&D Officer | 57 | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Jackson Tai
BRD | Director/Board Member | 73 | 06/23/06 |
William Keller
BRD | Director/Board Member | 75 | 17/17/17 |
Ge Li
CHM | Chairman | 56 | 01/10/01 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |